While rasagiline is currently the only treatment considered possibly useful by the MDS-Evidence Based Medicine for PD-associated fatigue, cognitive impairment is managed with acetylcholinesterase inhibitors, apathy with dopaminergic agents or acetylcholinesterase inhibitors, and anxiety and depression are commonly treated with antidepressants (18, 23). The gene discussed is ACHE; the disease is depressive symptom measurement.